Macrophages present pinocytosed exogenous antigen via MHC class I whereas antigen ingested by receptor-mediated endocytosis is presented via MHC class II.
Macrophages present exogenous Ag either via MHC class I or MHC class II molecules. We investigated whether the mode of hemagglutinin (HA) uptake influences the class of MHC molecule by which this Ag is presented. Normally, HA is ingested by receptor-mediated endocytosis, but this may be switched to macropinocytosis and pinocytosis by adding phorbol esters to the cells. This switch resulted in altered intracellular routing of ingested Ag and a transition from Ag presentation via MHC class II molecules to presentation via MHC class I molecules. Similarly, inhibition of receptor-mediated HA endocytosis, by treating the cells with the HA receptor destroying enzyme neuraminidase, abrogated Ag presentation via MHC class II molecules and induced presentation via MHC class I molecules. If, however, under these conditions, receptor-mediated uptake of HA was restored, by virtue of HA/anti-HA Ab interaction and subsequent uptake of HA via the Fc receptor, presentation via MHC class II was restored as well, whereas presentation of HA via MHC class I molecules was no longer detectable. We conclude that in macrophages the mode of Ag uptake is decisive in determining via which class of MHC molecules Ag is presented: pinocytosis and macropinocytosis produce exclusive presentation of exogenous Ag via MHC class I molecules whereas receptor-mediated endocytosis leads exclusively to presentation via class II molecules.
Laboratory for Experimental Internal Medicine, Academic Medical Centre, Amsterdam, The Netherlands. M.P.Peppelenbosch@amc.uva.nl
M P
MP
Peppelenbosch
M
M
DeSmedt
G
G
Pynaert
S J
SJ
van Deventer
J
J
Grooten
D000818:Animals; D017951:Antigen Presentation / Q000187:drug effects; D002451:Cell Compartmentation / Q000187:drug effects / Q000276:immunology; D002461:Cell Line, Transformed; D004705:Endocytosis / Q000187:drug effects / Q000276:immunology; D005110:Extracellular Space / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D005260:Female; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000276:immunology* / Q000378:metabolism; D015395:Histocompatibility Antigens Class I / Q000276:immunology / Q000378:metabolism*; D000949:Histocompatibility Antigens Class II / Q000276:immunology / Q000378:metabolism*; D009980:Influenza A virus / Q000276:immunology; D007424:Intracellular Fluid / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D008264:Macrophages / Q000276:immunology* / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D009439:Neuraminidase / Q000494:pharmacology; D010455:Peptides / Q000276:immunology / Q000378:metabolism; D010873:Pinocytosis / Q000187:drug effects / Q000276:immunology*; D011946:Receptors, Antigen / Q000502:physiology*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
D019267:Hemagglutinin Glycoproteins, Influenza Virus; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D010455:Peptides; D011946:Receptors, Antigen; D009439:Neuraminidase; D013755:Tetradecanoylphorbol Acetate